Survival outcomes with Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics

• by Mike Wenzel, Quynh Chi Le, Carolin Siech, Benedikt Hoeh, Konrad Klimek, Christian Happel, Fred Saad, Felix Preisser, Derya Tilki, Markus Graefen, Thomas Steuber, Tobias Maurer, Maximilian C. Kriegmair, Pierre I. Karakiewicz, Felix K. H. Chun, Daniel Groener, Philipp Mandel

• October 20, 2026

Stereotactic body radiation therapy in elderly patients with spinal metastases

• by Brock J. Gjesdal, Samuel Adida, Suchet Taori, Andrew H. Zureick, Serah Choi, John C. Flickinger, Pascal O. Zinn, James C. Bayley, Peter C. Gerszten, Roberta K. Sefcik

• October 16, 2026

2026 ASCO Breast Cancer Highlights: persevERA

Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH, discuss the persevERA trial and oral SERDS in metastatic breast cancer.

• October 15, 2026

• 1 min

Musings From the Power List: Jason Bock

Jason Bock shares his outlook on RNA-targeting therapies, personalized medicine, and the future of drug development

• by Jason Bock

• October 14, 2026

• 14 min